Alzheimer’s Drug Discontinued: What Went Wrong?

A close-up view of a variety of colorful pills and tablets stacked together

Alzheimer’s drugs clear deadly brain plaques but fail to halt memory loss, exposing a decades-long scientific chase that questions everything we thought we knew about the disease.

Story Snapshot

Aducanumab’s 2021 FDA approval promised to target Alzheimer’s root cause by removing amyloid plaques, yet discontinued in 2024 after limited cognitive benefits.
Over 200 failed trials reveal amyloid hypothesis flaws: plaques vanish, but symptoms persist due to late treatment timing.
Shift to early intervention and multi-target therapies like tau vaccines offers renewed hope amid billions in sunk costs.
Pharma giants like Biogen faced controversy, stock boosts, and layoffs, highlighting risks of accelerated approvals.
Experts agree: no cure yet, but partial amyloid validation pushes prevention-focused research forward.

Alzheimer’s Discovery and Early Drug Pursuits

Alois Alzheimer identified plaques and tangles in 1906, marking the disease’s hallmark pathology. The 1976 discovery of acetylcholine deficiency led to cholinesterase inhibitors like tacrine in 1993 and donepezil in 1996. These drugs eased symptoms by boosting neurotransmitter levels but ignored underlying causes. Memantine followed in 2003, modulating glutamate to protect neurons.

Amyloid Hypothesis Ignites High-Stakes Trials

Elan’s 1999 amyloid beta vaccine cleared plaques in mice, birthing the dominant theory that beta-amyloid accumulation drives Alzheimer’s. Human trials followed in the 2000s. 2008 autopsies confirmed plaque reduction without cognitive improvement, sowing early doubts. Biogen’s aducanumab hyped in 2015 after small studies showed clearance via monoclonal antibodies binding amyloid. Phase III trials exposed inconsistencies, fueling debate on mechanism limits.

2021 Approval and Swift Discontinuation

FDA granted aducanumab accelerated approval in 2021 as the first therapy targeting Alzheimer’s biology, despite advisory committee rejection over weak cognition data. Biogen and Eisai pushed amyloid monoclonal antibodies, claiming plaque-cognition links. Safety halted higher doses in 2019 due to brain swelling risks. By November 2024, Biogen discontinued it amid poor sales and unproven benefits.

Similar fates hit bapineuzumab and solanezumab in 2012, verubecestat in 2017 for toxicity, and Roche’s gantenerumab trials terminated post-failures. Over 200 trials by 2019 underscored late-stage intervention pitfalls—damage accumulates irreversibly before plaques dominate.

Stakeholders Clash in Power Dynamics

Biogen and Eisai pioneered anti-amyloid mAbs, securing revenue despite controversies. Eli Lilly chased mild Alzheimer’s effects with solanezumab; Roche advanced gantenerumab before halting. FDA and NIA balanced efficacy against safety, enabling trials via ADCS since 1991. Alzheimer’s Association recruited patients and tracked milestones. Prof. John Hardy, amyloid co-discoverer, urges multifactorial views. Pharma drives innovation, checked by regulators demanding data rigor.

Scientists finally reveal how this Alzheimer’s drug really works https://t.co/KWA0ei7L0p pic.twitter.com/ZjoPyMAc4x

— Georgette H Tarnow–Helping You Help Others (@YourCaregiving) March 17, 2026

Pfizer exited neuroscience in 2018, cutting 3000 jobs after flops. Patients numbering over 6 million in the US endure hope dashed by trial letdowns. Costs exceed $1 billion per failed drug, with approvals justifying $56,000 annual pricing.

Current Shifts and Future Pathways

Lecanemab gained 2023 approval with modest slowing via amyloid clearance. Ongoing gantenerumab Phase III and ACI-35 tau vaccines signal combo therapies. Prevention trials target asymptomatics since 2014. Consensus favors early action; amyloid plays a role but not alone—inflammation and tau demand equal focus. American values prize practical outcomes over hype, backing proven incremental gains.